Annual EBIT
-$360.92 M
-$69.53 M-23.86%
31 December 2023
Summary:
Madrigal Pharmaceuticals annual earnings before interest & taxes is currently -$360.92 million, with the most recent change of -$69.53 million (-23.86%) on 31 December 2023. During the last 3 years, it has fallen by -$154.25 million (-74.63%). MDGL annual EBIT is now -548.12% below its all-time high of $83.00 million.MDGL EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBIT
-$103.28 M
+$45.03 M+30.36%
30 September 2024
Summary:
Madrigal Pharmaceuticals quarterly earnings before interest & taxes is currently -$103.28 million, with the most recent change of +$45.03 million (+30.36%) on 30 September 2024. Over the past year, it has dropped by -$8.05 million (-8.45%). MDGL quarterly EBIT is now -187.40% below its all-time high of $118.17 million, reached on 30 September 2009.MDGL Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBIT
-$503.53 M
-$8.05 M-1.62%
30 September 2024
Summary:
Madrigal Pharmaceuticals TTM earnings before interest & taxes is currently -$503.53 million, with the most recent change of -$8.05 million (-1.62%) on 30 September 2024. Over the past year, it has dropped by -$166.61 million (-49.45%). MDGL TTM EBIT is now -638.64% below its all-time high of $93.48 million, reached on 31 March 2010.MDGL TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
MDGL EBIT Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -23.9% | -8.4% | -49.5% |
| 3 y3 years | -74.6% | -63.7% | -112.2% |
| 5 y5 years | -787.2% | -326.9% | -533.6% |
MDGL EBIT High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -74.6% | at low | -79.6% | +30.4% | -112.2% | at low |
| 5 y | 5 years | -787.2% | at low | -326.9% | +30.4% | -533.6% | at low |
| alltime | all time | -548.1% | at low | -187.4% | +30.4% | -638.6% | at low |
Madrigal Pharmaceuticals EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$103.28 M(-30.4%) | -$503.53 M(+1.6%) |
| June 2024 | - | -$148.31 M(+3.2%) | -$495.48 M(+15.2%) |
| Mar 2024 | - | -$143.70 M(+32.8%) | -$430.06 M(+19.2%) |
| Dec 2023 | -$360.92 M(+23.9%) | -$108.22 M(+13.6%) | -$360.92 M(+7.1%) |
| Sept 2023 | - | -$95.24 M(+14.9%) | -$336.92 M(+4.8%) |
| June 2023 | - | -$82.90 M(+11.2%) | -$321.38 M(+4.2%) |
| Mar 2023 | - | -$74.56 M(-11.5%) | -$308.43 M(+5.8%) |
| Dec 2022 | -$291.39 M(+20.5%) | -$84.22 M(+5.7%) | -$291.39 M(+7.2%) |
| Sept 2022 | - | -$79.69 M(+13.9%) | -$271.71 M(+6.5%) |
| June 2022 | - | -$69.95 M(+21.6%) | -$255.12 M(+3.4%) |
| Mar 2022 | - | -$57.52 M(-10.9%) | -$246.82 M(+1.9%) |
| Dec 2021 | -$241.85 M(+17.0%) | -$64.55 M(+2.3%) | -$242.28 M(+2.1%) |
| Sept 2021 | - | -$63.10 M(+2.4%) | -$237.28 M(+1.9%) |
| June 2021 | - | -$61.65 M(+16.4%) | -$232.97 M(+5.1%) |
| Mar 2021 | - | -$52.98 M(-11.0%) | -$221.65 M(+7.2%) |
| Dec 2020 | -$206.67 M(+117.6%) | -$59.55 M(+1.3%) | -$206.67 M(+16.7%) |
| Sept 2020 | - | -$58.79 M(+16.8%) | -$177.07 M(+24.3%) |
| June 2020 | - | -$50.33 M(+32.4%) | -$142.48 M(+24.0%) |
| Mar 2020 | - | -$38.01 M(+26.9%) | -$114.86 M(+20.9%) |
| Dec 2019 | -$94.97 M(+133.4%) | -$29.95 M(+23.8%) | -$94.97 M(+19.5%) |
| Sept 2019 | - | -$24.20 M(+6.6%) | -$79.47 M(+19.3%) |
| June 2019 | - | -$22.70 M(+25.3%) | -$66.61 M(+28.8%) |
| Mar 2019 | - | -$18.12 M(+25.4%) | -$51.73 M(+27.2%) |
| Dec 2018 | -$40.68 M(+26.9%) | -$14.45 M(+27.5%) | -$40.68 M(+15.8%) |
| Sept 2018 | - | -$11.33 M(+44.8%) | -$35.14 M(+8.3%) |
| June 2018 | - | -$7.83 M(+10.7%) | -$32.44 M(-1.9%) |
| Mar 2018 | - | -$7.07 M(-20.7%) | -$33.06 M(+3.1%) |
| Dec 2017 | -$32.06 M(+27.4%) | -$8.91 M(+3.2%) | -$32.06 M(+3.8%) |
| Sept 2017 | - | -$8.64 M(+2.3%) | -$30.90 M(-14.9%) |
| June 2017 | - | -$8.44 M(+38.9%) | -$36.31 M(+19.0%) |
| Mar 2017 | - | -$6.08 M(-21.6%) | -$30.51 M(+21.2%) |
| Dec 2016 | -$25.18 M(+678.7%) | -$7.75 M(-44.8%) | -$25.18 M(+37.2%) |
| Sept 2016 | - | -$14.05 M(+432.4%) | -$18.34 M(+254.5%) |
| June 2016 | - | -$2.64 M(+257.6%) | -$5.18 M(-76.5%) |
| Mar 2016 | - | -$738.00 K(-19.6%) | -$22.04 M(-47.1%) |
| Dec 2015 | -$3.23 M(-96.1%) | -$918.40 K(+4.4%) | -$41.63 M(-31.3%) |
| Sept 2015 | - | -$880.00 K(-95.5%) | -$60.61 M(-23.5%) |
| June 2015 | - | -$19.50 M(-4.1%) | -$79.18 M(-2.7%) |
| Mar 2015 | - | -$20.33 M(+2.2%) | -$81.38 M(-3.1%) |
| Dec 2014 | -$83.95 M | -$19.89 M(+2.3%) | -$83.95 M(-4.1%) |
| Sept 2014 | - | -$19.45 M(-10.4%) | -$87.50 M(-2.6%) |
| June 2014 | - | -$21.70 M(-5.3%) | -$89.85 M(-0.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2014 | - | -$22.91 M(-2.3%) | -$90.21 M(+3.0%) |
| Dec 2013 | -$87.56 M(+43.7%) | -$23.44 M(+7.6%) | -$87.56 M(+7.0%) |
| Sept 2013 | - | -$21.79 M(-1.2%) | -$81.82 M(+9.7%) |
| June 2013 | - | -$22.06 M(+8.9%) | -$74.56 M(+11.9%) |
| Mar 2013 | - | -$20.26 M(+14.4%) | -$66.63 M(+9.3%) |
| Dec 2012 | -$60.94 M(+34.1%) | -$17.70 M(+21.8%) | -$60.94 M(+14.0%) |
| Sept 2012 | - | -$14.54 M(+2.9%) | -$53.48 M(+4.5%) |
| June 2012 | - | -$14.13 M(-3.0%) | -$51.16 M(+4.3%) |
| Mar 2012 | - | -$14.56 M(+42.3%) | -$49.03 M(+7.9%) |
| Dec 2011 | -$45.43 M(+23.1%) | -$10.24 M(-16.2%) | -$45.43 M(+4.3%) |
| Sept 2011 | - | -$12.22 M(+1.7%) | -$43.56 M(+4.8%) |
| June 2011 | - | -$12.01 M(+9.5%) | -$41.57 M(+7.7%) |
| Mar 2011 | - | -$10.97 M(+31.1%) | -$38.61 M(+4.6%) |
| Dec 2010 | -$36.90 M(-145.8%) | -$8.37 M(-18.2%) | -$36.90 M(+3.9%) |
| Sept 2010 | - | -$10.23 M(+13.1%) | -$35.51 M(-138.2%) |
| June 2010 | - | -$9.04 M(-2.3%) | $92.89 M(-0.6%) |
| Mar 2010 | - | -$9.26 M(+32.6%) | $93.48 M(+16.1%) |
| Dec 2009 | $80.54 M(-185.9%) | -$6.98 M(-105.9%) | $80.54 M(+30.6%) |
| Sept 2009 | - | $118.17 M(-1498.0%) | $61.66 M(-174.3%) |
| June 2009 | - | -$8.45 M(-61.9%) | -$82.97 M(-14.9%) |
| Mar 2009 | - | -$22.20 M(-14.2%) | -$97.46 M(+4.0%) |
| Dec 2008 | -$93.71 M(+41.5%) | -$25.86 M(-2.2%) | -$93.71 M(+11.3%) |
| Sept 2008 | - | -$26.45 M(+15.3%) | -$84.19 M(+15.1%) |
| June 2008 | - | -$22.95 M(+24.4%) | -$73.13 M(+8.1%) |
| Mar 2008 | - | -$18.45 M(+12.9%) | -$67.65 M(+2.2%) |
| Dec 2007 | -$66.22 M(+11.9%) | -$16.34 M(+6.2%) | -$66.22 M(+5.3%) |
| Sept 2007 | - | -$15.39 M(-11.9%) | -$62.88 M(+1.3%) |
| June 2007 | - | -$17.47 M(+2.7%) | -$62.06 M(+4.3%) |
| Mar 2007 | - | -$17.01 M(+30.8%) | -$59.52 M(+3.6%) |
| Dec 2006 | -$59.15 M(-16.9%) | -$13.01 M(-10.8%) | -$57.44 M(-4.2%) |
| Sept 2006 | - | -$14.58 M(-2.4%) | -$59.92 M(-16.8%) |
| June 2006 | - | -$14.93 M(0.0%) | -$72.03 M(-14.0%) |
| Mar 2006 | - | -$14.93 M(-3.6%) | -$83.79 M(-4.1%) |
| Dec 2005 | -$71.18 M(+57.0%) | -$15.49 M(-41.9%) | -$87.36 M(+21.6%) |
| Sept 2005 | - | -$26.69 M(0.0%) | -$71.87 M(+59.1%) |
| June 2005 | - | -$26.69 M(+44.3%) | -$45.18 M(+144.3%) |
| Mar 2005 | - | -$18.50 M(+239.3%) | -$18.50 M(+239.3%) |
| Dec 2004 | -$45.35 M(+60.3%) | - | - |
| Mar 2004 | - | -$5.45 M | -$5.45 M |
| Dec 2003 | -$28.29 M(+288.0%) | - | - |
| Dec 2002 | -$7.29 M(+1718.5%) | - | - |
| Dec 2001 | -$401.00 K | - | - |
FAQ
- What is Madrigal Pharmaceuticals annual earnings before interest & taxes?
- What is the all time high annual EBIT for Madrigal Pharmaceuticals?
- What is Madrigal Pharmaceuticals annual EBIT year-on-year change?
- What is Madrigal Pharmaceuticals quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Madrigal Pharmaceuticals?
- What is Madrigal Pharmaceuticals quarterly EBIT year-on-year change?
- What is Madrigal Pharmaceuticals TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Madrigal Pharmaceuticals?
- What is Madrigal Pharmaceuticals TTM EBIT year-on-year change?
What is Madrigal Pharmaceuticals annual earnings before interest & taxes?
The current annual EBIT of MDGL is -$360.92 M
What is the all time high annual EBIT for Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals all-time high annual earnings before interest & taxes is $83.00 M
What is Madrigal Pharmaceuticals annual EBIT year-on-year change?
Over the past year, MDGL annual earnings before interest & taxes has changed by -$69.53 M (-23.86%)
What is Madrigal Pharmaceuticals quarterly earnings before interest & taxes?
The current quarterly EBIT of MDGL is -$103.28 M
What is the all time high quarterly EBIT for Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals all-time high quarterly earnings before interest & taxes is $118.17 M
What is Madrigal Pharmaceuticals quarterly EBIT year-on-year change?
Over the past year, MDGL quarterly earnings before interest & taxes has changed by -$8.05 M (-8.45%)
What is Madrigal Pharmaceuticals TTM earnings before interest & taxes?
The current TTM EBIT of MDGL is -$503.53 M
What is the all time high TTM EBIT for Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals all-time high TTM earnings before interest & taxes is $93.48 M
What is Madrigal Pharmaceuticals TTM EBIT year-on-year change?
Over the past year, MDGL TTM earnings before interest & taxes has changed by -$166.61 M (-49.45%)